{"id":{"repo_id":"clemson","oai_identifier":"oai:open.clemson.edu:all_theses-3412"},"canonical_url":"https://search.ndltd.org/etd/clemson/oai:open.clemson.edu:all_theses-3412","repository":{"repo_id":"clemson","name":"Clemson University","base_url":"https://open.clemson.edu/do/oai/"},"display":{"title":"INTERLEUKIN12/FASTI: A Novel Bi-Functional Fusion Protein for Cancer Immunogene Therapy","abstract":"Cancer is the second leading cause of disease death worldwide. Whereas cancer immunotherapy with cytokines in previous researches demonstrated effective in activating immune response against tumor cells, one major obstacle with the use of these cytokines is their severe side effects when delivered systemically at high doses. Another challenge is that tumor cells often lead to immune destruction by evading immunosurveillance of the innate immune system such as natural killer (NK) cells as well as of the Fas-mediated apoptosis by down-regulating their expression. In the present study, a novel fusion protein-IL-12/FasTI, consisting of mIL-12 and the transmembrane and intracellular domains of Fas, was successfully created. The fusion construct (pmIL-12/FasTI) in an expressing vector was transfected into the mouse pulmonary carcinoma cell line TC-1 and stable cell clones expressing the fusion protein were selected. In vitro studies confirmed the functions of the bifunctional protein as the induction of apoptosis of tumor cells and NK cell activation by increased IFN-Î³ production and cytotoxicity. This new approach may generate a promising therapeutic agent for tumor treatment when combined with tumor cell-specific gene delivery vehicles such as nanoparticles.","abstract_html":"Cancer is the second leading cause of disease death worldwide. Whereas cancer immunotherapy with cytokines in previous researches demonstrated effective in activating immune response against tumor cells, one major obstacle with the use of these cytokines is their severe side effects when delivered systemically at high doses. Another challenge is that tumor cells often lead to immune destruction by evading immunosurveillance of the innate immune system such as natural killer (NK) cells as well as of the Fas-mediated apoptosis by down-regulating their expression. In the present study, a novel fusion protein-IL-12/FasTI, consisting of mIL-12 and the transmembrane and intracellular domains of Fas, was successfully created. The fusion construct (pmIL-12/FasTI) in an expressing vector was transfected into the mouse pulmonary carcinoma cell line TC-1 and stable cell clones expressing the fusion protein were selected. In vitro studies confirmed the functions of the bifunctional protein as the induction of apoptosis of tumor cells and NK cell activation by increased IFN-Î³ production and cytotoxicity. This new approach may generate a promising therapeutic agent for tumor treatment when combined with tumor cell-specific gene delivery vehicles such as nanoparticles.","abstract_has_math":false,"creators":["Yang, Xi"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis","degree_discipline":"Biological Sciences","degree_department":null,"school":null,"contributors":["Dr. Yanzhang Wei, Committee Chair","Dr. Charlie Rice","Dr. Jeremy Tzeng","Dr. Xianzhong Yu"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:12:33Z","subjects":["apoptosis","cancer immunity","Fas","gene therapy","Interleukin-12","Natural killer cells"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://open.clemson.edu/all_theses/2407","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://open.clemson.edu/all_theses/2407","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.clemson.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Aopen.clemson.edu%3Aall_theses-3412","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Yanzhang Wei, Committee Chair","Dr. Charlie Rice","Dr. Jeremy Tzeng","Dr. Xianzhong Yu"]},{"key":"dc:creator","label":"Author","values":["Yang, Xi"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.created","label":"Dc Date Created","values":["2016-05-01T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["apoptosis","cancer immunity","Fas","gene therapy","Interleukin-12","Natural killer cells"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://open.clemson.edu/all_theses/2407"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cancer is the second leading cause of disease death worldwide. Whereas cancer immunotherapy with cytokines in previous researches demonstrated effective in activating immune response against tumor cells, one major obstacle with the use of these cytokines is their severe side effects when delivered systemically at high doses. Another challenge is that tumor cells often lead to immune destruction by evading immunosurveillance of the innate immune system such as natural killer (NK) cells as well as of the Fas-mediated apoptosis by down-regulating their expression. In the present study, a novel fusion protein-IL-12/FasTI, consisting of mIL-12 and the transmembrane and intracellular domains of Fas, was successfully created. The fusion construct (pmIL-12/FasTI) in an expressing vector was transfected into the mouse pulmonary carcinoma cell line TC-1 and stable cell clones expressing the fusion protein were selected. In vitro studies confirmed the functions of the bifunctional protein as the induction of apoptosis of tumor cells and NK cell activation by increased IFN-Î³ production and cytotoxicity. This new approach may generate a promising therapeutic agent for tumor treatment when combined with tumor cell-specific gene delivery vehicles such as nanoparticles."]},{"key":"dc:title","label":"Title","values":["INTERLEUKIN12/FASTI: A Novel Bi-Functional Fusion Protein for Cancer Immunogene Therapy"]}]}],"canonical_facts":{"dc:contributor":["Dr. Yanzhang Wei, Committee Chair","Dr. Charlie Rice","Dr. Jeremy Tzeng","Dr. Xianzhong Yu"],"dc:creator":["Yang, Xi"],"dc:date.created":["2016-05-01T07:00:00Z"],"dc:description.abstract":["Cancer is the second leading cause of disease death worldwide. Whereas cancer immunotherapy with cytokines in previous researches demonstrated effective in activating immune response against tumor cells, one major obstacle with the use of these cytokines is their severe side effects when delivered systemically at high doses. Another challenge is that tumor cells often lead to immune destruction by evading immunosurveillance of the innate immune system such as natural killer (NK) cells as well as of the Fas-mediated apoptosis by down-regulating their expression. In the present study, a novel fusion protein-IL-12/FasTI, consisting of mIL-12 and the transmembrane and intracellular domains of Fas, was successfully created. The fusion construct (pmIL-12/FasTI) in an expressing vector was transfected into the mouse pulmonary carcinoma cell line TC-1 and stable cell clones expressing the fusion protein were selected. In vitro studies confirmed the functions of the bifunctional protein as the induction of apoptosis of tumor cells and NK cell activation by increased IFN-Î³ production and cytotoxicity. This new approach may generate a promising therapeutic agent for tumor treatment when combined with tumor cell-specific gene delivery vehicles such as nanoparticles."],"dc:identifier":["https://open.clemson.edu/all_theses/2407"],"dc:subject":["apoptosis","cancer immunity","Fas","gene therapy","Interleukin-12","Natural killer cells"],"dc:title":["INTERLEUKIN12/FASTI: A Novel Bi-Functional Fusion Protein for Cancer Immunogene Therapy"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-11-19T07:12:33Z"}